Journals / Üroonkoloji Bülteni / 2021 / Cilt: 20 - Sayı: 2

The Investigation of Treatment Effects on Serum Biochemical Parameters in Bladder Cancer Diseases

Tedavinin Serum Üzerindeki Etkilerinin Araştırılması Mesane Kanseri Hastalıklarında Biyokimyasal Parametreler

Pages
107–110
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The decrease in arginine and ADMA levels in non-muscle invasive BC patients is thought to be promising, and these markers may be useful in monitoring the diagnosis and treatment of patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The most common cancer in smokers is bladder cancer (BC).
📊
Key Findings & Data:Materials and Methods: Blood samples were collected from all patients (n=30) and controls (group 1) prior to transurethral resection of bladder tumour (TURBT) (group 2), 20 days after TURBT (group 3) and at the end of intravesical immunotherapy 74 (group 4).
💡
Conclusion & Impact:Conclusion: The decrease in arginine and ADMA levels in non-muscle invasive BC patients is thought to be promising, and these markers may be useful in monitoring the diagnosis and treatment of patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The most common cancer in smokers is bladder cancer (BC). Intravesical chemo immunotherapies are used to lower the risk of progression in patients who are at risk. Bacillus Calmette-Guérin immunotherapy is the most effective adjuvant therapy discovered. We aimed to evaluate the levels of arginine, citrulline, ornithine, symmetrically dimethylated arginine (SDMA), N-monomethyl-Larginine. (L-NMMA) or asymmetrically dimethylated arginine (ADMA) in patients with BC, as well as their relationship with methylarginine. Materials and Methods: Blood samples were collected from all patients (n=30) and controls (group 1) prior to transurethral resection of bladder tumour (TURBT) (group 2), 20 days after TURBT (group 3) and at the end of intravesical immunotherapy 74 (group 4). The levels of serum methylated arginine were measured using ABSCIEX API 3200 tandem mass spectrometry system in positive ESI mode. Results: In comparison to group 2, group 1’s ADMA and arginine/total methylated arginine levels were 98 significantly lower (p=0.035 and p=0.049, respectively), while SDMA/ADMA, L-NMMA and arginine/ADMA levels (p=0.001, p=0.008 and p=0.017) increased, and no statistical difference was found for other parameters (p>0.05). When compared to group 3, ADMA, arginine, citrulline, methylated arginines and L-NMMA levels in group 2 (p=0.035, p=0.001, p=0.015, p=0.032, p=0.032) increased, while SDMA/ADMA levels (p=0.041) decreased. Conclusion: The decrease in arginine and ADMA levels in non-muscle invasive BC patients is thought to be promising, and these markers may be useful in monitoring the diagnosis and treatment of patients.

Özet

Amaç: Sigara içenlerde en sık görülen kanser mesane kanseridir (BC). Hastalarda progresyon riskini azaltmak için intravezikal kemo immünoterapiler kullanılır. kim risk altında. Bacillus Calmette-Guérin immünoterapisi, keşfedilen en etkili adjuvan tedavidir. Arginin, sitrülin, ornitin, simetrik olarak dimetillenmiş arginin (SDMA), N-monometil-Larginin. (L-NMMA) veya BC'li hastalarda asimetrik olarak dimetillenmiş arginin (ADMA), yanı sıra metilarginin ile ilişkileri. Gereç ve Yöntemler: Tüm hastalardan (n=30) ve kontrollerden (grup 1) mesane tümörünün transüretral rezeksiyonu (TURBT) öncesinde kan örnekleri alındı. (grup 2), TURBT'den 20 gün sonra (grup 3) ve intravezikal immünoterapi sonunda 74 (grup 4). Serum metillenmiş arginin seviyeleri kullanılarak ölçüldü. Pozitif ESI modunda ABSCIEX API 3200 tandem kütle spektrometrisi sistemi. Bulgular: Grup 2 ile karşılaştırıldığında, grup 1 ADMA ve arginin/toplam metillenmiş arginin seviyeleri 98 anlamlı olarak daha düşüktü (sırasıyla p=0.035 ve p=0.049), SDMA/ADMA, L-NMMA ve arginin/ADMA düzeyleri (p=0.001, p=0.008 ve p=0.017) yükselirken, diğer parametrelerde istatistiksel olarak fark bulunmadı. (p>0.05). Grup 3 ile karşılaştırıldığında, grup 2'de ADMA, arginin, sitrülin, metillenmiş argininler ve L-NMMA düzeyleri (p=0.035, p=0.001, p=0.015, p=0.032, p=0.032) artarken, SDMA/ADMA seviyeleri (p=0.041) azaldı. Sonuç: Kas invaziv olmayan BC hastalarında arginin ve ADMA düzeylerindeki düşüşün umut verici olduğu düşünülmektedir ve bu belirteçlerin bu hastalarda yararlı olabileceği düşünülmektedir. hastaların tanı ve tedavisinin takibi.

🔖

Cite This Article

DİNÇEL, A. S., ABUŞOĞLU, S., ÜNLÜ, A., TEMELTAŞ, G., ÜÇER, O., ARI, Z., KOSOVA, F. (2022). The Investigation of Treatment Effects on Serum Biochemical Parameters in Bladder Cancer Diseases. Üroonkoloji Bülteni, Cilt: 20 - Sayı: 2, 107–110. https://ajindex.com/articles/645738

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Luo K-W, Lung W-Y, Xie C, et al. EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget 2018;9:12261-12272
  2. Drăgoescu PO, Tudorache Ş, Drocaş AI, et al. Improved diagnosis and long-term recurrence rate reduction for nonmuscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. Rom J Morphol Embryol 2017;58:1279-1283
  3. Kim SJ, Yoo BC, Uhm CS, Lee SW. Posttranslational arginine methylation of lamin A/C during myoblast fusion. Biochim Biophys Acta 2011;1814:308-317
  4. Nicole YS, Sean YN, Stephen LT, Vladimir L. Protein arginine methyltransferase expression and activity during myogenesis, Biosci Rep 2018;38:BSR20171533. doi: 10.1042/BSR20171533
  5. Stouth DW, van Lieshout TL, Shen NY, Ljubicic V. Regulation of skeletal muscle plasticity by protein arginine methyltransferases and their potential roles in neuromuscular disorders. Front Physiol 2017;8:870
  6. Paik WK, Paik DC, Kim S. Historical review: the field of protein methylation. Trends Biochem Sci 2007;32:146-152
  7. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005;18:263-272
  8. Yongchul L, Suyeun Y, Jung-A Y, et al. The prognostic significance of protein arginine methyltransferase 6 expression in colon cancer. Oncotarget 2018;9:9010-9020
  9. McCabe MT, Mohammad HP, Barbash O, Kruger RG. Targeting histone methylation in cancer. Cancer J 2017;23:292-301
  10. Wysocka J, Allis CD, Coonrod S. Histone arginine methylation and its dynamic regulation. Front Biosci 2006;11:344-355
  11. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett 2011;585:2024-2031
  12. Yoshimatsu M, Toyokawa G, Hayami S, et al, Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011;128:562-573
  13. Kielstein JT, Cooke JP. Should we measure asymmetric dimethylarginine in patients with coronary artery disease? Clin Chem 2007;53:161-163
  14. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer 2013;13:37-50
  15. Li T, Kong AN, Ma Z, et al. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant. Oncotarget 2016;7:20236-20248. doi: 10.18632/oncotarget.7752
  16. Di Gangi IM, Chiandetti L, Gucciardi A, et al. Simultaneous quantitative determination of